Renee Lester

Bio-Sketch: Dr. Renee Lester is a Medical Oncologist with the Cancer Care Program of Eastern Health in St. John’s, Newfoundland. She is a Clinical Associate Professor within the Discipline of Oncology at the Faculty of Medicine, Memorial University of Newfoundland. She received her MD from Memorial University of Newfoundland in 2010 and completed a residency in Internal Medicine at Memorial in 2013. She completed her Medical Oncology training at the University of Calgary in 2015.

Dr. Lester is involved in the treatment of patients with breast, lung, head and neck, and neuroendocrine malignancies. She is also involved in clinical research and is an investigator in a number of clinical trials.

Publications:

Albiges L, Fay AP, Xie W, Krajewski K, McDermott DF, Heng DY, Dariane C, DeVelasco G, Lester R, Escudier B, Choueiri TK. Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma.Eur J Cancer. 2015 Nov;51(17):2580-6. doi: 10.1016/j.ejca.2015.08.017. Epub 2015 Sep 4

Azad AA, Leibowitz-Amit R, Eigl BJ, Lester R, Wells JC, Murray RN, Kollmannsberger C, Heng DY, Joshua AM, Chi KN. A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer. Prostate. 2014 Nov;74(15):1544-50. doi: 10.1002/pros.22872. Epub 2014 Aug 29

Lee-Ying R, Lester R, Heng D. Current management and future perspectives of metastatic renal cell carcinoma. Int J Urol. 2014 Sep;21(9):847-55. doi: 10.1111/iju.12502. Epub 2014 May 27. Review

Azad AA, Eigl BJ, Leibowitz-Amit R, Lester R, Kollmannsberger C, Murray N, Clayton R, Heng DY, Joshua AM, Chi KN. Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status. Eur Urol. 2015 Mar;67(3):441-7. doi: 10.1016/j.eururo.2014.01.030. Epub 2014 Jan 31